In pancreatic ductal adenocarcinoma, combination therapy with anti-PD-L1 antibody and AMD3100, a selective CXCR4 antagonist, increases T cell accumulation in tumor tissue by suppressing CXCR4-mediated exclusion of cytotoxic T cells [127]. Here, CXCR4 is linked to pancreatic ductal adenocarcinoma.